Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Erectile Dysfunction | 2 | 2021 | 20 | 1.770 |
Why?
|
| Hypoglycemia | 2 | 2017 | 57 | 1.230 |
Why?
|
| Nursing Homes | 7 | 2021 | 534 | 1.130 |
Why?
|
| Hypoglycemic Agents | 2 | 2017 | 189 | 1.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2021 | 609 | 1.050 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2021 | 4 | 0.890 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 189 | 0.880 |
Why?
|
| Hypertension | 2 | 2022 | 543 | 0.770 |
Why?
|
| Electronic Health Records | 2 | 2021 | 281 | 0.680 |
Why?
|
| Sulfonylurea Compounds | 1 | 2017 | 15 | 0.660 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 27 | 0.660 |
Why?
|
| Weight Gain | 1 | 2017 | 179 | 0.580 |
Why?
|
| Blood Glucose | 2 | 2018 | 452 | 0.550 |
Why?
|
| Pain | 3 | 2021 | 305 | 0.510 |
Why?
|
| Risk Assessment | 3 | 2016 | 1589 | 0.500 |
Why?
|
| Pregnancy in Adolescence | 1 | 2013 | 23 | 0.500 |
Why?
|
| Algorithms | 2 | 2022 | 892 | 0.470 |
Why?
|
| Tretinoin | 1 | 2011 | 43 | 0.430 |
Why?
|
| Depression, Postpartum | 1 | 2013 | 131 | 0.420 |
Why?
|
| Behavioral Symptoms | 2 | 2021 | 15 | 0.420 |
Why?
|
| Carcinoma | 1 | 2011 | 115 | 0.400 |
Why?
|
| Mothers | 1 | 2013 | 224 | 0.400 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 725 | 0.400 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 167 | 0.390 |
Why?
|
| Retrospective Studies | 5 | 2021 | 4519 | 0.380 |
Why?
|
| Premature Birth | 2 | 2022 | 99 | 0.340 |
Why?
|
| United States | 9 | 2021 | 6278 | 0.330 |
Why?
|
| Cohort Studies | 3 | 2021 | 2091 | 0.330 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 349 | 0.310 |
Why?
|
| Male | 11 | 2022 | 23388 | 0.300 |
Why?
|
| Humans | 18 | 2022 | 49898 | 0.290 |
Why?
|
| Adult | 6 | 2021 | 13395 | 0.260 |
Why?
|
| Pain Measurement | 2 | 2021 | 253 | 0.240 |
Why?
|
| Prevalence | 4 | 2022 | 1132 | 0.240 |
Why?
|
| Perinatal Death | 1 | 2022 | 5 | 0.230 |
Why?
|
| Tadalafil | 1 | 2021 | 2 | 0.230 |
Why?
|
| Aged | 9 | 2021 | 10948 | 0.230 |
Why?
|
| Carbolines | 1 | 2021 | 7 | 0.230 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 2107 | 0.230 |
Why?
|
| Treatment Outcome | 3 | 2021 | 3891 | 0.230 |
Why?
|
| Prescription Drug Misuse | 1 | 2022 | 22 | 0.220 |
Why?
|
| Drug Utilization | 2 | 2021 | 222 | 0.220 |
Why?
|
| Neuralgia | 1 | 2021 | 16 | 0.220 |
Why?
|
| Nitrates | 1 | 2021 | 15 | 0.220 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2022 | 34 | 0.220 |
Why?
|
| Female | 12 | 2022 | 26566 | 0.220 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 4243 | 0.220 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 69 | 0.210 |
Why?
|
| Symptom Assessment | 1 | 2020 | 36 | 0.200 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 153 | 0.200 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 112 | 0.200 |
Why?
|
| Pain Management | 1 | 2021 | 113 | 0.190 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 278 | 0.190 |
Why?
|
| Homes for the Aged | 1 | 2021 | 147 | 0.190 |
Why?
|
| Anticonvulsants | 1 | 2020 | 80 | 0.190 |
Why?
|
| Young Adult | 4 | 2018 | 3699 | 0.190 |
Why?
|
| Epilepsy | 1 | 2020 | 73 | 0.180 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 178 | 0.170 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 47 | 0.170 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 35 | 0.170 |
Why?
|
| Anticoagulants | 1 | 2021 | 404 | 0.170 |
Why?
|
| Pregnancy | 4 | 2022 | 2092 | 0.160 |
Why?
|
| Middle Aged | 4 | 2018 | 13558 | 0.150 |
Why?
|
| Immunization | 1 | 2016 | 118 | 0.150 |
Why?
|
| Vaccines | 1 | 2016 | 77 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 612 | 0.140 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2015 | 32 | 0.140 |
Why?
|
| Heart Failure | 1 | 2021 | 669 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1950 | 0.140 |
Why?
|
| Incidence | 1 | 2017 | 1131 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 690 | 0.130 |
Why?
|
| Medicare | 3 | 2021 | 464 | 0.130 |
Why?
|
| Maternal Age | 1 | 2013 | 31 | 0.130 |
Why?
|
| Insulin | 1 | 2018 | 667 | 0.130 |
Why?
|
| Prognosis | 1 | 2017 | 1257 | 0.120 |
Why?
|
| Rhode Island | 1 | 2013 | 82 | 0.120 |
Why?
|
| Maternal Behavior | 1 | 2013 | 34 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1155 | 0.120 |
Why?
|
| Biomarkers | 1 | 2017 | 998 | 0.120 |
Why?
|
| Administration, Topical | 1 | 2011 | 44 | 0.110 |
Why?
|
| Keratinocytes | 1 | 2011 | 51 | 0.110 |
Why?
|
| Prenatal Care | 1 | 2013 | 181 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 832 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 753 | 0.100 |
Why?
|
| Social Support | 1 | 2013 | 336 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 384 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2022 | 1158 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2011 | 553 | 0.100 |
Why?
|
| Logistic Models | 1 | 2013 | 1168 | 0.100 |
Why?
|
| Time Factors | 1 | 2016 | 3184 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 1426 | 0.090 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2011 | 399 | 0.090 |
Why?
|
| Risk Factors | 2 | 2016 | 4286 | 0.090 |
Why?
|
| Comorbidity | 2 | 2021 | 1003 | 0.080 |
Why?
|
| Adolescent | 2 | 2018 | 5397 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 2298 | 0.070 |
Why?
|
| Stillbirth | 1 | 2022 | 18 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2021 | 28 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 59 | 0.050 |
Why?
|
| Analgesics | 1 | 2021 | 87 | 0.050 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 15 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 176 | 0.050 |
Why?
|
| Medicare Part D | 1 | 2020 | 34 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2022 | 762 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2021 | 205 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 69 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 348 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 252 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 860 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2016 | 46 | 0.040 |
Why?
|
| Quality of Life | 1 | 2021 | 736 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 152 | 0.040 |
Why?
|
| Obstetric Labor Complications | 1 | 2015 | 22 | 0.040 |
Why?
|
| Data Collection | 1 | 2016 | 390 | 0.030 |
Why?
|